Open for inclusion

A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Cancer type: Head and Neck cancer

Phase: II

Principal Investigator: Bratland Åse

Country: NO

Keywords: Norway, Oslo, Head and Neck, Nivolumab, Ipilimumab

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02823574?term=CA209-714&rank=1